Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
3(23%)
Results Posted
20%(2 trials)

Phase Distribution

Ph phase_1
8
62%
Ph phase_3
4
31%
Ph phase_2
1
8%

Phase Distribution

8

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
8(61.5%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
4(30.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(10)

Detailed Status

Completed10
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (61.5%)
Phase 21 (7.7%)
Phase 34 (30.8%)

Trials by Status

active_not_recruiting215%
completed1077%
recruiting18%

Recent Activity

3 active trials
Showing 5 of 13
recruitingphase_2

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077
active_not_recruitingphase_3

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
completedphase_3

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

NCT05952869
active_not_recruitingphase_3

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291
completedphase_3

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

NCT05952856
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07058077Phase 2

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Recruiting
NCT06008756Phase 3

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Active Not Recruiting
NCT05952869Phase 3

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

Completed
NCT06492291Phase 3

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Active Not Recruiting
NCT05952856Phase 3

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Completed
NCT06772792Phase 1

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

Completed
NCT05934292Phase 1

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

Completed
NCT06772779Phase 1

A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)

Completed
NCT06699355Phase 1

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

Completed
NCT06699329Phase 1

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

Completed
NCT06691906Phase 1

A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

Completed
NCT06658652Phase 1

The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)

Completed
NCT06625814Phase 1

A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13